SCHEMBL25686555

SCHEMBL25686555

C[C@@H]1CN(C(C)(C)C)C(=O)N1

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.37
▸ ALOX5 P09917 3/20 0.34
▸ MAPT P10636 2/20 0.32
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25464205 0.78 POLB (0.35) POLBMAPT
SCHEMBL25464230 0.78 LMNA (0.32) POLBMAPTLMNA
SCHEMBL24777790 0.76 POLB (0.36) POLBMAPT
SCHEMBL21350281 0.76 POLB (0.40) POLBMAPT
SCHEMBL19961296 0.76 POLB (0.36) POLBMAPT
SCHEMBL25464216 0.75 POLB (0.33) POLB
SCHEMBL25464221 0.75 LMNA (0.31) POLBMAPTLMNA
SCHEMBL22414234 0.72 ALOX5 (0.39) POLBALOX5
SCHEMBL21669887 0.72 ALOX5 (0.42) POLBALOX5MAPT
SCHEMBL22414233 0.72 ALOX5 (0.39) POLBALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147458-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN RESEARCH & DEVELOPMENT, LLC 2023-05-11 — — US disclosed
US-20230147458-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN RESEARCH & DEVELOPMENT, LLC 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147458-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS IL17A, IL23R, IL15 POLB 4606/4885ALOX5 1117/4885MAPT 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback